The annual Clinical Trials in Alzheimer’s Disease (CTAD) Congress brings together global experts to discuss developments in Alzheimer’s disease (AD) clinical research and showcase researchers’ work on AD trials. This article describes a recently initiated Phase II trial of a novel anti-tau monoclonal antibody, BMS-986446, the design for which was presented at the 17th CTAD Congress in Madrid, Spain, on 31st October 2024.
